Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc., located in the North San Diego County city of Carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. We are the pioneer in the discovery and development of antisense drugs with more than 1300 patents.
Ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. Our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. We are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. Join us and experience our unique culture while you develop and expand your career.
797 articles with Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that the California Life Sciences Association (CLSA), the trade association representing California's life sciences sector and its board of directors will honor Ionis with the 2019 Pantheon DiNA™ Award for Company of the Year.
California Life Sciences Association (CLSA), the trade association representing California’s life sciences sector, has announced the 2019 Pantheon DiNATM Awards slate of honorees.
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
Ionis Pharmaceuticals, Inc., the leader in antisense therapeutics, announced that management will present a company overview at the following investor conferences
Ionis Pharmaceuticals, Inc. announced that GSK exercised its option to license Ionis' antisense medicines for people with chronic hepatitis B virus infection following positive Phase 2 results.
Waylivra was rejected by the FDA last year but gained approval in Europe in May. The publication of final Phase III data in the New England Journal of Medicine could support a potential bid for regulatory approval in the U.S.
New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome
Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc., announced that the final study results from the Phase 3 APPROACH study evaluating WAYLIVRA® (volanesorsen) in patients with familial chylomicronemia syndrome (FCS) were published in the August 8th issue of The New England Journal of Medicine (NEJM).
Ionis Pharmaceuticals, Inc. reported its financial results for the second quarter and year-to-date 2019 and recent business highlights.
Webcast scheduled for Wednesday, August 7th at 11:30 a.m. Eastern Time
Ionis Pharmaceuticals, Inc., the leader in antisense therapeutics, announced that management will present a company overview at the BMO Prescription for Success Healthcare Conference at 9:20 a.m. ET on Tuesday, June 25, 2019 in New York, NY.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced the appointment of a new member to its board of directors effective immediately – Joan E. Herman, MBA, MS, president and chief executive officer of Herman and Associates, LLC
Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders
Ionis Pharmaceuticals, Inc. announced that Stanley T. Crook, M.D., Ph.D., chairman of the board and chief executive officer, will present a general corporate update and 30-year retrospective in conjunction with its 2019 Annual Meeting of Stockholders and Open House on Thursday, June 6 at 2:10 p.m. Pacific Time in Carlsbad, CA.
Ionis Pharmaceuticals, Inc. reported its financial results for the first quarter of 2019 and recent business highlights.
Ionis launches new corporate brand that reflects company's industry-leading innovation and unique culture of saying "yes" to patients
Ionis Pharmaceuticals, Inc. unveiled its new corporate brand in a campaign inspired by its unique culture and history of developing transformative therapies for seemingly untreatable diseases.
Positive clinical data at AAN 2019 reinforces Ionis' commitment to delivering life-changing medicines to patients with neurological diseases
Twelve presentations highlighting transformational medicines for SMA, hATTR, Huntington's disease, ALS, prion disease and others
Webcast scheduled for Thursday, May 9th at 11:30 a.m. Eastern Time
Ionis Pharmaceuticals, Inc. announced that management will present a general corporate update in conjunction with its 2019 Annual Meeting of Stockholders and Open House on Thursday, June 6 at 2:10 p.m. Pacific Time in Carlsbad, CA.
Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, announced that Brett P. Monia, Ph.D., has been appointed to the company's board of directors.
Biotech and pharma companies from across the globe share data and news in a weekly roundup.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its partner, Akcea Therapeutics, affiliate of Ionis Pharmaceuticals, received a positive opinion for WAYLIVRA™ by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA